

## **Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026**

**DENVER, CO / ACCESS Newswire / May 18, 2026** / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

### **Company Webcast**

The webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at <https://lythampartners.com/spring2026/> or directly at <https://app.webinar.net/8p9EoXv752z>. The webcast will also be available for replay following the event. It will also be accessible on the Investors section of the Company’s website at <https://investors.aytubio.com/> under Events & Presentations.

### **1×1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/spring2026invreg/>.

### **About Aytu BioPharma**

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company’s prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company’s medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit [aytubio.com](http://aytubio.com) or follow us on LinkedIn.

### **Contacts for Investors**

Ryan Selhorn, Chief Financial Officer  
Aytu BioPharma, Inc.  
[rselhorn@aytubio.com](mailto:rselhorn@aytubio.com)

Robert Blum  
Lytham Partners  
aytu@lythampartners.com

**SOURCE:** Aytu BioPharma, Inc.

[View the original press release on ACCESS Newswire](#)